Corrigendum: Cost-Effective, Safe, and Personalized Cell Therapy for Critical Limb Ischemia in Type 2 Diabetes Mellitus (Frontiers in Immunology, (2019), 10, 10.3389/fimmu.2019.01151)

  1. Soria-Juan, B.
  2. Escacena, N.
  3. Capilla-González, V.
  4. Aguilera, Y.
  5. Llanos, L.
  6. Tejedo, J.R.
  7. Bedoya, F.J.
  8. Juan, V.
  9. De la Cuesta, A.
  10. Ruiz-Salmerón, R.
  11. Andreu, E.
  12. Grochowicz, L.
  13. Prósper, F.
  14. Sánchez-Guijo, F.
  15. Lozano, F.S.
  16. Miralles, M.
  17. Del Río-Solá, L.
  18. Castellanos, G.
  19. Moraleda, J.M.
  20. Sackstein, R.
  21. García-Arranz, M.
  22. García-Olmo, D.
  23. Martín, F.
  24. Hmadcha, A.
  25. Soria, B.
Journal:
Frontiers in Immunology

ISSN: 1664-3224

Year of publication: 2020

Volume: 11

Type: Erratum

DOI: 10.3389/FIMMU.2020.02029 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

Data source: Scopus